Guidelines Detail

Navbar

Guidelines
Compendia & Templates
Education & Research
Patient Resources
Business & Policy
Global

Guidelines COVID-19 Resources Treatment by Cancer Type Detection, Prevention, and Risk Reduction Supportive Care Specific Populations Guidelines for Patients Guidelines With Evidence Blocks NCCN Framework For Resource Stratification Harmonized Guidelines International Adaptations and Translations Guidelines Process Guidelines Panels and Disclosure Permission to Cite or Use NCCN Content Recently Updated Guidelines Submission Request to the Guidelines Panels

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Bladder Cancer Bone Cancer Breast Cancer Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal Stromal Tumors (GIST) Gestational Trophoblastic Neoplasia Hairy Cell Leukemia Head and Neck Cancers

Hepatobiliary Cancers Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Malignant Peritoneal Mesothelioma Malignant Pleural Mesothelioma Melanoma: Cutaneous Melanoma: Uveal Merkel Cell Carcinoma Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes Myeloproliferative Neoplasms Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas

Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic Light Chain Amyloidosis Systemic Mastocytosis T-Cell Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vulvar Cancer Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Wilms Tumor (Nephroblastoma)

Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Colorectal Cancer Screening

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment: Colorectal Lung Cancer Screening

Prostate Cancer Early Detection

Adult Cancer Pain Antiemesis Cancer-Associated Venous Thromboembolic Disease Cancer-Related Fatigue

Distress Management Hematopoietic Cell Transplantation Hematopoietic Growth Factors Management of Immunotherapy-Related Toxicities

Palliative Care Prevention and Treatment of Cancer-Related Infections Smoking Cessation Survivorship

Adolescent and Young Adult (AYA) Oncology

Cancer in People with HIV

Older Adult Oncology

Acute Lymphoblastic Leukemia (adult) Acute Lymphoblastic Leukemia (pediatric) Acute Myeloid Leukemia Adolescents and Young Adults with Cancer Adrenal Tumors Anal Cancer Anemia and Neutropenia - Low Red and White Blood Cell Counts Basal Cell Skin Cancer B-Cell Lymphomas - Diffuse Large B-Cell Lymphoma B-Cell Lymphomas - Follicular Lymphoma B-Cell Lymphomas - Mantle Cell Lymphoma Bladder Cancer Bone Cancer Brain Cancer - Gliomas Breast Cancer - DCIS Breast Cancer Breast Cancer - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Central Nervous System Cancers - Primary Central Nervous System Lymphoma Cervical Cancer Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia

Colon Cancer Colorectal Cancer Screening Distress Management - Distress During Cancer Care Esophageal Cancer Gallbladder and Bile Duct Cancers Graft-Versus-Host Disease Head and Neck Cancers - Nasopharyngeal Cancer Head and Neck Cancers - Oral Cancers Head and Neck Cancers - Oropharyngeal Cancer Hodgkin Lymphoma Immunotherapy Side Effects: CAR T-Cell Therapy Immunotherapy Side Effects: Immune Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Malignant Pleural Mesothelioma Melanoma Multiple Myeloma Mycosis Fungoides/Sézary Syndrome Myelodysplastic Syndromes Myeloproliferative Neoplasms

Nausea and Vomiting Neuroendocrine Tumors Non-Small Cell Lung Cancer - Early and Locally Advanced Non-Small Cell Lung Cancer - Metastatic Ovarian Cancer Pancreatic Cancer Peripheral T-Cell Lymphoma Primary Cutaneous Lymphomas Prostate Cancer: Advanced Stage Prostate Cancer: Early Stage Rectal Cancer Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Stomach Cancer Survivorship Care for Cancer-Related Late and Long-Term Effects Survivorship Care for Healthy Living Systemic Mastocytosis Thyroid Cancer Uterine Cancer Waldenström Macroglobulinemia

About Clinical Practice Guidelines Development and Update of Guidelines

Transparency Process Guidelines Panels Meeting Schedule

Disclosure Policies and Potential Conflicts of Interest

Guidelines Panels

Guideline Steering Committee

Submission Request History

Compendia & Templates Compendia Chemotherapy Order Templates

NCCN Compendia Drugs and Biologics Compendium Biomarkers Compendium

Imaging AUC Compendium Radiation Therapy Compendium Subscribe to NCCN Compendium

Recognition Program

Browse by Cancer Type View Chemotherapy Order Templates User Guide

EHR Integration Chemotherapy Order Templates Committee

Subscribe to NCCN Templates Chemotherapy Order Templates Reviewer Acknowledgement

Education & Research Events and Programs Oncology Research Program JNCCN Publications

Continuing Education Calendar of Events

Annual Congress: Hematologic Malignancies 2022 Annual Congress: Hematologic Malignancies Sponsor and Exhibitor Prospectus

Nursing Events Annual Conference

Oncology Research Program (ORP) Current Opportunities ORP Recent News ORP Grant History

Scientific Publications Clinical Trials Young Investigator Awards Informed Consent Language Database

Best Practices for Biorepositories Shared Resources Disclosure Policy

About JNCCN

Subscribe to JNCCN

JNCCN Email Updates

Business & Policy Business Policy and Advocacy Program

Corporate Council Academy Trends U.S. Surveys Trends Global Surveys Flash Updates

Order Free Pocket Guidelines and Guidelines for Patients Advertising Opportunities Research Tools: REMS Employer Toolkit Employer Resources

Virtual Reimbursement Resource Room and App Health Information Technology Licenses Embargo Policy Firewall Policy

Policy and Advocacy Program Oncology Policy Summits

Policy Priority: Improve and Facilitate Quality Cancer Care Policy Priority: Ensure Patient Accessibility

Policy Priority: Increase Use of Guidelines State Oncology Society Forum

Global Global Program Global Clinical Resources Global Support Opportunities Global Policy Contact NCCN Global NCCN Joins the Global Plea for Peace in Ukraine and Recognizes the Profound Impact to Cancer Care

Africa Asia Caribbean

Europe Latin America Middle East & North Africa

Worldwide

Clinical Guidelines Translations Guidelines for Patients Translations

Distress Thermometer Tool Translations International Adaptations

Framework for Resource Stratification Harmonized Guidelines

Global Corporate Council Global Academy

Trends Global Surveys eBulletin Global Edition

Home
Guidelines
Guidelines Detail

NCCN Guidelines

COVID-19 Resources
Treatment by Cancer Type
Detection, Prevention, and Risk Reduction
Supportive Care
Specific Populations
Guidelines for Patients
Guidelines With Evidence Blocks
NCCN Framework For Resource Stratification
Harmonized Guidelines
International Adaptations and Translations
Guidelines Process
Guidelines Panels and Disclosure
Permission to Cite or Use NCCN Content
Recently Updated Guidelines
Submission Request to the Guidelines Panels
- Submission Request History

Multiple Myeloma

Guidelines

NCCN Guidelines Version 5.2022

- Active (symptomatic) Myeloma

- Multiple Myeloma

- Smoldering (asymptomatic) Myeloma

- Solitary Plasmacytoma

Evidence Blocks

NCCN Guidelines with Evidence Blocks Version 5.2022

Guidelines for Patients

Multiple Myeloma-English Version 2022
Multiple Myeloma-Korean Version 2022
Multiple Myeloma-Russian Version 2019

Educational Events and Programs

Calendar of Events

Continuing Education

New Treatment Options in Multiple Myeloma
NCCN Guidelines® Insights - Multiple Myeloma, Version 3.2022
Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
NCCN Pharmacy Updates: CAR-T Therapy in Multiple Myeloma
Archived Monthly Oncology Tumor Boards: New Options in Treatment of Relapsed/Refractory Multiple Myeloma
Toxicities of CAR T-Cell Therapy: Beyond CRS and Neurotoxicity
Recorded Presentation from the NCCN Pharmacy Updates: CAR-T Therapy in Multiple Myeloma
Updates to Management of Patients with Multiple Myeloma

International

Translations

Arabic Version 3.2022
Chinese Version 3.2022
French Version 3.2022
German Version 3.2022
Italian Version 3.2022
Japanese Version 3.2022
Korean Version 3.2022
Portuguese (Latin America) Version 3.2022
Russian Version 3.2022
Spanish (European Editions) Version 3.2022
Spanish (Latin America) Version 5.2022

Adaptations

Portuguese (Latin America) Version 3.2017

Harmonized

English (Caribbean) Version 4.2018
English (Africa) Version 4.2021

Disclosures

Disclosure Policy
Panel Member Disclosures
Panel Member Disclosures by Meeting Date
End User License Agreement